GEHC

Study of nearly 13,000 adult general anesthesia cases found clinician use of End-tidal Control softwarei at a large multisite academic medical center was associated with a reduction in fresh gas flow, sevoflurane consumption and estimated CO2 equivalents during maintenance of anesthesia End-tidal Control software automatically adjusts fresh gas flow concentrations of O2 and anesthetic agent concentrations to maintain targets set by the clinician, and, as one study shows, with more accuracy versus manual control for safeii, low-flowiii anesthesia GE HealthCare (NASDAQ:GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the use of End-

MINItrace Magni combines a compact, self-shielded design with automated operation to help healthcare providers establish and expand local production of radioisotopes used in PET tracers Copper-64 expands the PETtrace Solid Target Platform beyond Gallium-68, supporting research in both copper-based imaging agents and the potential Copper-64/Copper-67 theranostic pair GE HealthCare (NASDAQ:GEHC) today announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 (⁶⁴Cu) production. Together, the developments reflect the company’s focus on helping institutions build the production c

Barclays initiated coverage of GE HealthCare with a rating of Overweight and set a new price target of $85.00

GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.About GE HealthCare Technologies Inc.GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical di

Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing mar

The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.04 per share of Common Stock for the third quarter of 2026, an increase of 14% from the previous quarter. The dividend will be payable on November 13, 2026, to all shareholders of record as of October 23, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next

8-K - GE HealthCare Technologies Inc. (0001932393) (Filer)

GE HealthCare (NASDAQ:GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE:T), a Fortune 50 company, to its Board of Directors, effective January 4, 2027. Mr. Desroches brings more than 30 years of leadership experience across finance, governance, and large-scale technology and digital transformation."Pascal is a highly respected executive and accomplished financial leader whose experience spans corporate strategy, capital deployment, and investor engagement," said H. Lawrence Culp, Jr., Chairman of the Board of Directors, GE HealthCare. "His perspective will further strengthen our Board as we execute on ou

Needham initiated coverage of GE HealthCare with a rating of Buy and set a new price target of $93.00

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

3 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

Two leading academic medical centers will be the first health systems to implement CareIntellect for Operations Solution provides a 72-hour view of emerging operational bottlenecks and delivers actionable guidance tied to discharge, imaging, transfer, and other capacity needs Combines GE HealthCare’s proprietary AI models and more than two decades of hospital operations expertise GE HealthCare (NASDAQ:GEHC) today announced CareIntellect™ for Operations, a new AI-enabled Software-as-a-Service (SaaS) application designed to help health systems forecast capacity constraints up to 72 hours in advance, providing comprehensive unit-, department-, and enterprise-level views of emerging b

StarGuide™ GXi is 510(k) pending with the U.S. FDA following its recent CE Mark, marking continued momentum in bringing next-generation 4D CZT SPECT/CT innovation to clinicians and expanding access to advanced molecular imaging technologies Designed for the theranostics era, StarGuide GX incorporates a versatile, future-ready SPECT/CT system capable of imaging across a broad spectrum of energy levels – including investigational alpha emitters – while delivering ultra-high sensitivity, high-resolution imaging and accurate quantitation to support precision care Engineered to help nuclear medicine departments improve efficiency without compromising image quality, the system leverages no

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

Following U.S. FDA 510(k) clearance and Japanese regulatory approval, Photonova Spectra has also achieved CE Mark, supporting expanded research and clinical adoption across Europe and other global markets Powered by the company’s proprietary Deep Silicon detector technology and engineered for ultra‑high definition clarity, on‑demand spectral and spatial imaging, and fast, wide‑coverage acquisition, Photonova Spectra brings together rich detail, robust performance, and an Effortless Workflow to help support confident detection, characterization, and monitoring GE HealthCare (NASDAQ:GEHC) recently achieved CE Mark for Photonova Spectra,i an advanced photon-counting computed tomography

Vivid™ Explorer, Vivid™ Advanced and Vivid™ Focus systems bring cSound™ imaging with capabilities designed for routine echocardiography, comprehensive cardiac imaging and interventional care GE HealthCare (NASDAQ:GEHC) today announced three additions to its Vivid™ cardiovascular ultrasound portfolio – Vivid™ Explorer1, Vivid™ Advanced1 and Vivid™ Focus1 – each designed to address distinct imaging and workflow needs across a range of cardiology care settings. The systems will be showcased at the European Society of Cardiology (ESC) Congress 2026, taking place August 28–31 in Munich, Germany. The number of people living with cardiovascular disease worldwide has doubled since 1991.2 As car

GE HealthCare (NASDAQ:GEHC) is announcing that members of its management team will present at the following upcoming investor conference: Wells Fargo 21st Annual Health Conference – Wednesday, September 9, 2026 at 10:15 am ET/9:15am CT A webcast for the event can be accessed on the GE HealthCare website: https://investor.gehealthcare.com/news-events/events at the date and time listed above. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers fo

4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)